Baird had a note out last week:
Regeneron compettive concerns overdone, says RW Baird
Baird believes Regeneron (REGN) investor concerns regarding Allergan's (AGN) DARPin Phase ll data are overdone as the firm believes approval would be roughly five years out. Baird said the market may be misinterpreting the molecule's half-life and that its potency may be similar at best to Regeneron's Elyea. Shares of Regeneron are Outperform rated with a $205 price target.